Finally, we explored the therapeutic potential of the above observations, by investigating the effects of the RhoA‐GEF (guanine exchange factor) inhibitor Rhosin, which selectively inhibits RhoA activity [31], on the invasive capacity of siControl‐ and siWNT5A‐treated melanoma cells. The gene discussed is RHOA; the disease is melanoma.